Merck KGaA is taking a relaxed view to M&A and licensing activities in its healthcare segment, believing its existing portfolio and pipeline is enough to be focusing on for the time being.
So said CEO Belén Garijo when asked by Scrip whether the return to more rational valuations for biotechs meant that the environment for dealmaking had become more attractive. She noted...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?